Tag: GlobeNewswire

NANTERRE (FRANCE)
NOVEMBER 2, 2026

SALES BROADLY STABLE IN Q3

INTERIORS DIVESTITURE ON TRACK FOR Q4 CLOSING

FY 2026 GUIDANCE CONFIRMED

• STRONG SALES OUTPERFORMANCE IN MOST KEY REGIONS
  • Q3 sales of €5.1bn, outperforming global automotive production by 100bps
  • Continued outperformance in Europe, North America, alongside double-digit organic growth in Asia excluding China; gradual progress in China
  • Strong momentum in Electronics (+7.0%) and Clarion (+22.0%); Seating improving significantly compared to H1

• DISCIPLINED EXECUTION IN A CHALLENGING MARKET ENVIRONMENT
  • Continued rigorous cost control and progress on operational efficiency initiatives, including EU-FORWARD and SIMPLIFY
  • Increased inflationary pressures actively managed through operational actions and customer pass-through mechanisms, to secure appropriate compensation
  • Implementation of Lighting transformation plan, with actions underway to restore competitiveness

• INTERIORS DIVESTURE TO CLOSE IN Q4, A MAJOR STEP IN IGNITE ROADMAP
  • All required regulatory approvals secured, with closing expected in Q4 2026
  • Expected net debt reduction of more than €1.0bn and gross debt reduction of more than €1.4bn, further strengthening FORVIA’s financial profile
• FULL-YEAR 2026 GUIDANCE CONFIRMED

Martin FISCHER, Chief Executive Officer of FORVIA, declared:

“The third quarter marked an improvement in our sales trajectory, supported by the strong momentum of Electronics, continued outperformance in Europe and North America and gradual progress in China. These results reflect the relevance of our technologies and the increasing value they bring to our customers.
The upcoming divestiture of Interiors is a major milestone in our IGNITE roadmap that will simplify our portfolio and significantly strengthen our balance sheet.
Across the Group, we continue to foster accountability and empower our teams to take ownership and drive performance. Combined with rigorous cost control, disciplined management of inflationary pressures and a strong focus on cash generation, this approach supports the delivery of our full-year objectives.”

• The Board of Directors, under the chairmanship of Pierre-André de Chalendar, met on October 30, 2026 and reviewed the present press release.
• All financial terms used in this press release are explained at the end of this document, under the section “Definitions of terms used in this document”.
• All figures are presented post IFRS 5.
• All figures related to worldwide or regional automotive production refer to the S&P Global Mobility forecast dated October 15, 2026.

STABLE ORGANIC SALES AT 5.1BN IN Q3, WITH IMPROVED MOMENTUM

In the third quarter of 2026, consolidated sales reached €5.08 billion, marking an improvement in FORVIA’s sales trajectory and an outperformance versus automotive production:

• Organic sales were broadly stable in Q3 at -0.6%, while they declined by 1.5% over the first nine months of the year.
• In Q3, FORVIA outperformed automotive production by 100bps, compared with an underperformance of 80bps over the first nine months.

		Q3 2025	Organic	Currency	Q3 2026
Group sales (€M)		5,029	-30	+80	5,079
YoY change			-0.6%	+1.6%	+1.0%
Outperformance vs auto production*			+100bps
* Source: S&P Mobility October 2026. Auto production declined by 1.6% to 22.7 m units

		9M 2025	Organic	Currency	9M 2026
Group sales (€M)		16,015	-239	-188	15,588
YoY change			-1.5%	-1.2%	-2.7%
Outperformance vs auto production			-80bps
* Source: S&P Mobility October 2026. Auto production declined by 0.7% to 67.8 m units

Q3 GLOBAL OUTPERFORMANCE OF 100 BPS DRIVEN BY EUROPE, NORTH AMERICA AND REST OF ASIA; PROGRESS IN CHINA

In €m (IFRS 5)	Q3 2026	Q3 2025	Reported Change	Organic Change	Perf vs. auto prod (pts)
EMEA	2,342	2,256	+3.8%	+3.8%	+6
o/w Europe	2,290	2,204	+3.9 %	+4.1%	+4
AMERICAS	1,379	1,334	+3.4%	+1.0%	+4
o/w North America	1,226	1,201	+2.1%	+0.4%	+5
ASIA	1,358	1,440	-5.7%	-9.0%	-8
o/w China	945	1,058	-10.7%	-17.2%	-11
o/w Rest of Asia	413	381	+8.4%	+13.6%	+7
GROUP	5,079	5,029	+1.0%	-0.6%	+1

• EUROPE: outperformance supported by Seating and Electronics

In Europe, sales advanced by 4.1% on an organic basis, representing an outperformance of 390 basis points. This was driven by solid activity at Seating and double-digit growth in Electronics.

• NORTH AMERICA: outperformance essentially driven by Clean Mobility

Organic sales were slightly up 0.4% in Q3, representing an outperformance of 510 basis points. This was primarily driven by a strong activity of Clean Mobility, as well as continued expansion of Clarion.

• CHINA: progress with Chinese OEMs reduced underperformance compared to H1

Organic sales declined by 17.2% in Q3, reflecting continued weakness in production among international OEMs. At the same time, FORVIA saw encouraging progress with Chinese OEMs, notably supported by the recovery in BYD production and continued growth with Chery.

• Rest of ASIA: continued strong momentum

FORVIA sustained the first-half trajectory with 13.6% organic growth, supported by continued success of Clarion.

STRONG MOMENTUM IN ELECTRONICS, PROGRESS IN SEATING AND RESILIENT SALES AT VALUE CLUSTER

In €m (IFRS 5)	Q3 2026	Q3 2025	Reported change	Organic Change
GROWTH CLUSTER	2,637	2,610	+1.0%	-1.0%
Seating	1,796	1,834	-2.1%	-4.4%
Electronics	841	777	+8.3%	+7.0%
VALUE CLUSTER	2,442	2,419	+1.0%	-0.3%
Clean Mobility	948	959	-1.2%	-3.0%
Lifecycle Solutions	247	237	+4.5%	+3.8%
Lighting	814	862	-5.6%	-7.8%
Clarion	430	360	+19.6%	+22.0%
Others	3	1
GROUP	5,079	5,029	+1.0%	-0.6%

Growth cluster: Organic sales declined by 1.0%, a significant improvement compared with H1 (-4.8%).

• Electronics maintained strong momentum, with organic sales up 7.0%, supported by continued success in radar and energy management technologies, particularly in Europe.
• Seating organic sales declined by 4.4%, with the decline halved compared with H1, reflecting a gradual recovery in China and solid growth in Europe.

Value cluster: Organic sales were broadly stable.

• Clean Mobility performance (-3.0%) reflected powertrain market dynamics, with strong activity in North America, resilient demand in Europe and a sharp decline in China.
• Lifecycle Solutions grew 3.8% organically, continuing its steady expansion in Aftermarket and Special Original Equipment.
• Lighting sales declined by 7.8%, with business trends remaining broadly in line with the expected path towards stabilization in 2027.
• Clarion Electronics maintained strong organic growth of 22.0%, driven by Japanese OEMs in Asia and North America.

DISCIPLINED EXECUTION IN A CHALLENGING MARKET ENVIRONMENT

In a challenging environment marked by persistent cost inflation and supply chain pressures, FORVIA maintained strong operational discipline and continued to execute on its key performance improvement initiatives.

The Group remained focused on:

Offsetting cost inflation (raw materials, energy, memory chips and PCBs) through supply chain optimization, contractual indexation mechanisms and customer recoveries to secure appropriate compensation,

Delivering fixed cost reductions through the continued execution of the EU-FORWARD and SIMPLIFY programs,

Advancing the Lighting turnaround plan, with dedicated actions across R&D, industrial performance and SG&A to progressively restore competitiveness.

FINAL STEPS TOWARDS INTERIORS CLOSING IN Q4 2026

The proposed divestiture of Interiors has reached a major milestone with the receipt of all required regulatory approvals, including clearances from all relevant antitrust authorities.

The remaining pre-closing steps continue to progress according to plan. Closing of the transaction is expected in Q4 2026.

As previously communicated, the transaction will reduce net debt by more than
€1.0 billion and gross debt by more than €1.4 billion.

The full allocation of proceeds to debt reduction will materially strengthen FORVIA’s balance sheet, enabling the Group to address most of its 2027 maturities and further enhance its financial flexibility.

2026 FULL-YEAR GUIDANCE CONFIRMED

Based on S&P Mobility’s October estimates, global automotive production is expected to decline by 4.2% in the fourth quarter of 2026.

Supported by its nine-month sales performance and disciplined management of costs and inflationary pressures, FORVIA confirms its full-year 2026 guidance*:

• Sales between €20bn and €21bn, at constant exchange rates
• Operating margin between 6.0% and 6.5% of sales
• Net Cash flow ≥3.0% of sales
• Net debt/Adjusted EBITDA ratio at 1.5x at December 31, 2026

*Based on:

• S&P Mobility’s latest forecast of 91.6 million light vehicle production in 2026; and

• the assumption that no material changes will occur in tariffs or trade restrictions in effect and that there is no material deterioration in the macroeconomic environment or significant supply chain disruptions
• 2025 average exchange rates: EUR/USD = 1.13, EUR/CNY = 8.11

A webcast will be held today, Monday November 2, 2026, at 8:00am (Paris time).

FORVIA’s Q3 2026 sales presentation will be available before the webcast on FORVIA’s website: www.forvia.com

If you wish to follow the presentation using the webcast, please access the following link:
https://edge.media-server.com/mmc/p/e2b92j8u
A replay will be available as soon as possible.

You may also follow the presentation via conference call (Code: 9786432):
France:   +33 1 70 91 87 04
United Kingdom:  +44 1 212 818 004
United States:   +1 718 705 8796

AGENDA

• February 26, 2027: 2026 Full-year results (before market hours)

Press	Analysts
Christophe MALBRANQUE Director Influence Groupe +33 (0) 6 21 96 23 53 christophe.malbranque@forvia.com	Adeline MICKELER Group Vice President Investor Relations +33 (0) 6 61 30 90 90 adeline.mickeler@forvia.com
Audrey ÉPÈCHE Head of Media Relations +33 (0) 6 15 98 23 53 audrey.epeche@forvia.com	Sébastien LEROY Group Deputy Investor Relations Director +33 (0) 6 26 89 33 69 sebastien.leroy@forvia.com

FORVIA, a global automotive technology supplier, comprises the complementary technology and industrial strengths of Faurecia and HELLA. With over 137 500 people, including more than 12,000 R&D engineers across 40+ countries, FORVIA provides a unique and comprehensive approach to the automotive challenges of today and tomorrow. Composed of 6 business groups and a strong IP portfolio of over 12,400 patents, FORVIA is focused on becoming the preferred innovation and integration partner for OEMs worldwide. In 2025, the Group achieved a consolidated revenue of 26.2 billion euros prior to IFRS 5. FORVIA SE is listed on the Euronext Paris market under the FRVIA mnemonic code and is a component of the SBF 120 index. FORVIA aims to be a change maker committed to foreseeing and making the mobility transformation happen. www.forvia.com

DISCLAIMER

This presentation contains certain forward-looking statements concerning FORVIA. Such forward-looking statements represent trends or objectives and cannot be construed as constituting forecasts regarding FORVIA’s future results or any other performance indicator. In some cases, you can identify these forward-looking statements by forward-looking words, such as “estimate,” “expect,” “anticipate,” “project,” “plan,” “intend,” “objective”, “believe,” “forecast,” “foresee,” “likely,” “may,” “should,” “goal,” “target,” “might,” “would,”, “will”, “could,”, “predict,” “continue,” “convinced,” and “confident,” the negative or plural of these words and other comparable terminology. Forward looking statements in this document include, but are not limited to, financial projections and estimates and their underlying assumptions including, without limitation, assumptions regarding present and future business strategies (including the successful integration of HELLA within the FORVIA Group), expectations and statements regarding FORVIA’s operation of its business, and the future operation, direction and success of FORVIA’s business. Although FORVIA believes its expectations are based on reasonable assumptions, investors are cautioned that these forward-looking statements are subject to numerous various risks, whether known or unknown, and uncertainties and other factors, all of which may be beyond the control of FORVIA and could cause actual results to differ materially from those anticipated in these forward-looking statements. For a detailed description of these risks and uncertainties and other factors, please refer to public filings made with the Autorité des Marchés Financiers (“AMF”), press releases, presentations and, in particular, to those described in the chapter 2.”Risk factors & Risk management” of FORVIA’s 2024 Universal Registration Document filed by FORVIA with the AMF on March 7, 2025 under number D. 24-0080 (a version of which is available on www.forvia.com). Subject to regulatory requirements, FORVIA does not undertake to publicly update or revise any of these forward-looking statements whether as a result of new information, future events, or otherwise. Any information relating to past performance contained herein is not a guarantee of future performance. Nothing herein should be construed as an investment recommendation or as legal, tax, investment or accounting advice. The historical figures related to HELLA included in this presentation have been provided to FORVIA by HELLA within the context of the acquisition process. These historical figures have not been audited or subject to a limited review by the auditors of FORVIA. FORVIA HELLA remains a listed company. For more information on FORVIA HELLA, more information is available on www.hella.com. This presentation does not constitute and should not be construed as an offer to sell or a solicitation of an offer to buy FORVIA securities.

APPENDICES

FIRST-NINE MONTHS SALES BY BUSINESS GROUP AND REGION

By Business Group

In €m (IFRS 5)	9M 2026	9M 2025	Reported Change	Organic change
GROWTH CLUSTER	8,159	8,509	-4,1%	-3.6%
Seating	5,638	6,128	-8.0%	-7.7%
Electronics	2,521	2,381	+5,9%	+7.1%
VALUE CLUSTER	7,412	7,490	-1.0%	+0.8%
Clean Mobility	2,896	3,001	-3.5%	-1.6%
Lifecycle Solutions	761	734	+3.7%	+4.2%
Lighting	2,548	2,712	-6.0%	-5.7%
Clarion	1,206	1,043	+15.6%	+22.6%
Others	17	16	–	–
GROUP	15,588	16,015	-2.7%	-1.5%

By Region
In €m (IFRS 5)	9M 2026	9M 2025	Reported Change	Organic change	Perf vs. auto prod (pts)
EMEA	7,659	7,566	+1.2%	+1.3%	+2
o/w Europe	7,507	7,408	+1.3%	+1.5%	+1
AMERICAS	3,982	3,960	+0.6%	+3.5%	+4
o/w North America	3,560	3,580	-0.6%	+3.2%	+5
ASIA	3,947	4,490	-12.1%	-10.6%	-10
o/w China	2,749	3,316	-17.1%	-18.6%	-13
o/w Rest of Asia	1,198	1,174	+2.0%	+12.1%	+8
GROUP	15,588	16,015	-2.7%	-1.5%	-1

PRELIMINARY STATEMENT ON INTERIORS DIVESTMENT (IFRS5)

On February 24, 2026, FORVIA announced its intention to divest its Interiors business. Subsequently, on April 26, 2026, the Group signed a definitive agreement with Apollo, subject to customary regulatory approvals and closing conditions.

In accordance with IFRS5 requirements, the Interiors business has been classified as a discontinued operation since December 31, 2025. Consequently, the assets and liabilities related to the business were reported as held for sale as of June 30, 2026.

As a result, the financial performance of the Interiors business is presented separately from continuing operations in the Group’s consolidated financial statements for the first half of 2026 and comparative periods.

To facilitate the assessment of the Group’s underlying financial performance and balance sheet trajectory, FORVIA also provides selected indicators, notably net debt and leverage, on a pre-IFRS5 basis, as the expected proceeds from the transaction are not reflected in IFRS5 net debt figures prior to closing.

DEFINITIONS OF TERMS USED IN THIS DOCUMENT

Sales growth

FORVIA’s year-on-year sales evolution is made of three components:

• A “Currency effect”, calculated by applying average currency rates for the period to the sales of the prior year,
• A “Scope effect” (acquisition/divestment),
• And “Growth at constant currencies”.

As “Scope effect”, FORVIA presents all acquisitions/divestments, whose sales on an annual basis amount to more than €250 million.

Other acquisitions below this threshold are considered as “bolt-on acquisitions” and are included in “Growth at constant currencies”.

Operating income

Operating income is the FORVIA group’s principal performance indicator. It corresponds to net income of fully consolidated companies before:

• Amortization of intangible assets acquired in business combinations.
• Other non-recurring operating income and expense, corresponding to material, unusual and non-recurring items including reorganization expenses and early retirement costs, the impact of exceptional events such as the discontinuation of a business, the closure or sale of an industrial site, disposals of non-operating buildings, impairment losses recorded for property, plant and equipment or intangible assets, as well as other material and unusual losses.
• Income on loans, cash investments and marketable securities; Finance costs.
• Other financial income and expense, which include the impact of discounting the pension benefit obligation and the return on related plan assets, the ineffective portion of interest rate and currency hedges, changes in value of interest rate and currency instruments for which the hedging relationship does not satisfy the criteria set forth in relationship cannot be demonstrated under IFRS 9, and gains and losses on sales of shares in subsidiaries.
• Taxes.
• Net result from discontinued operations

Adjusted EBITDA

In compliance with the ESMA (European Securities and Markets Authority) regulation, the term “Adjusted EBITDA” has been used since January 1, 2022.

Net cash flow

Net cash flow is defined as follows: Net cash from (used in) operating and investing activities less (acquisitions)/disposal of equity interests and businesses (net of cash and cash equivalents), other changes and proceeds from disposal of financial assets, and new or extended leases. Repayment of IFRS 16 debt is not included.

Net financial debt

Net financial debt is defined as follows: Gross financial debt less cash and cash equivalents and derivatives classified under non-current and current assets. It includes the lease liabilities (IFRS 16 debt).

Attachment

• 2026 11 02 PR Q3 SALES EN

Forensic accounting expert strengthens dispute advisory and investigations capabilities in Australia

BRISBANE, Australia, Nov. 02, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Daniel Heywood as a Senior Managing Director in the Forensic and Litigation Consulting segment. He will help clients navigate complex commercial disputes, investigations and regulatory matters.

Mr. Heywood, who is based in Brisbane, brings more than 17 years of forensic accounting experience. His areas of expertise include the quantification of economic loss, contract and post-acquisition disputes, class actions, professional negligence matters, insurance claims, insolvency litigation, forensic investigations, asset tracing and wage underpayment matters.

“Daniel brings a valuable combination of forensic accounting expertise, commercial judgement and experience working alongside legal teams on complex disputes and investigations,” said Dawna Wright, Head of the Forensic and Litigation Consulting segment in Australia at FTI Consulting. “His appointment strengthens our ability to support clients in Queensland and across Australia when they need clear, independent analysis of complex financial issues.”

Mr. Heywood has advised clients across aviation, construction, consumer goods, financial services, healthcare, mining, real estate, shipping and transportation. His experience includes preparing preliminary assessments of claims and financial exposure, advising on claim strategy, developing and evaluating causation arguments, critiquing claims and expert reports and assessing settlement offers.

He also has experience serving as an expert witness and independent advisor. His engagements have included shareholder and joint venture disputes, completion accounts and other post-acquisition matters, regulatory remediation programmes, class actions and investigations into alleged fraud, corruption and financial misconduct.

Mr. Heywood previously spent five years leading the in-house forensic accounting and investigations division of a top-tier law firm and also worked in the fraud and credit division of a global bank. He is a member of Chartered Accountants Australia and New Zealand and the Australian Institute of Company Directors.

Commenting on his appointment, Mr. Heywood said, “Organisations facing a dispute or investigation need expert analysis that is technically rigorous, commercially focused and clearly communicated. I look forward to working with colleagues across FTI Consulting to help clients understand their financial exposure, evaluate their options and make informed decisions in complex and high-stakes matters.”

About FTI Consulting
FTI Consulting, Inc. is a leading global expert firm for organisations facing crisis and transformation, with more than 8,200 employees located in 32 countries and territories as of September 30, 2026. In certain jurisdictions, FTI Consulting’s services are provided through distinct legal entities that are separately capitalised and independently managed. The Company generated $3.8 billion in revenues during fiscal year 2025. More information can be found at www.fticonsulting.com.

FTI Consulting, Inc.  
Level 20, CP1
345 Queen Street
Brisbane, QLD 4000
Australia

Investor Contact:   
Mollie Hawkes 
+1.617.747.1791 
mollie.hawkes@fticonsulting.com 

Media Contact:
Gemma Ellis
+61 864 301 326
Gemma.Ellis@fticonsulting.com

HANGZHOU, China, Nov. 01, 2026 (GLOBE NEWSWIRE) — Geely Automobile Holdings Limited (0175.HK) reported total sales of 310,183 vehicles in October, surpassing 300,000 units for the first time this year and marking the eighth consecutive month of YoY and MoM growth. Sales increased 6% from September.

New energy vehicle (NEV) sales across the Geely Auto brand, Lynk & Co and Zeekr brands reached a record 214,996 units in October, up 21% year on year. NEVs accounted for 69% of total monthly sales, also a new high.

The Geely Auto brand sold 255,742 vehicles in October, up 8% YoY. Sales of Geely NEV models reached a new monthly record of 153,385 units, increasing 18% YoY and 20% MoM.

Lynk & Co recorded sales of 21,958 vehicles, up 19% MoM. Sales of its new energy models reached 18,521 units, an increase of 9% from September.

Zeekr delivered 32,483 vehicles in October, up 52% YoY, marking the seventh consecutive month in which deliveries exceeded 30,000 units.

Geely Auto Group continued to strengthen its international business, with exports to markets outside China exceeding 100,000 vehicles for the fifth consecutive month. October exports volume reached 107,153 vehicles, up 158% YoY. New energy vehicle exports reached a record 82,565 units, surging 506% YoY and accounting for 77% of total overseas exports, reflecting the growing contribution of NEVs to the Group’s international business.

The Group’s overseas expansion is increasingly supported by stronger brand recognition. In October, Geely Auto Group made its first appearance at the Paris Motor Show with all three brands to showcase a diverse line-up of models. The Group also presented key technologies, including its SEA-S architecture and intelligent electric drive systems, highlighting the group’s engineering capabilities and technological strengths in intelligent electrification.

The Geely Monjaro EM-i and Lynk & Co 07 GT made their European debuts at the Paris Motor Show, while Zeekr presented its premium technology-focused vehicle line-up. Deliveries of the Zeekr 9X in Europe are scheduled to begin in January 2027.

Geely Auto Group continued to deepen its presence in Europe, with combined sales of the Geely Auto brand, Lynk & Co and Zeekr brands in the region exceeding 10,000 vehicles for the first time in September.

In the UK, Geely Auto brand reached a major milestone in expanding its local retail network, signing an agreement with Lithia Group, the UK’s second-largest automotive retailer, for its 100th retail outlet in the country. Geely Auto brand has also surpassed 10,000 cumulative vehicle registrations in the UK within just 11 months of entering the market, with monthly registrations exceeding 5,000 vehicles in September 2026 alone.

About Geely Auto Group

Geely Auto Group is a leading global automotive company headquartered in Hangzhou, China. Part of Zhejiang Geely Holding Group, Geely Auto Group develops and manufactures passenger vehicles under the Geely, Lynk & Co, and Zeekr brands.

With a strong focus on technology innovation, electrification, and sustainable mobility, Geely Auto Group operates world-class R&D centers and manufacturing facilities across China, Europe, and key international markets. The Group is committed to delivering safe, high-quality, and intelligent vehicles enabled by advanced technologies such as hybrid powertrains, full-electric architectures, smart connectivity, and autonomous driving systems.

As a global company, Geely Auto Group continues to expand its international presence through strategic partnerships, localized operations, and industry-leading platforms. Geely strives to create mobility solutions that are greener, smarter, and more accessible, driving forward the future of sustainable transportation.

Media Contact
Contact Person: Janet Chen
Email: media@geely.com

Hotel101-Madrid, the 680-room global prototype, has recorded its strongest monthly performance to date, providing further support for the Company’s asset-light condotel model as it advances its international expansion.

Latest Photo of 680-room Hotel101-Madrid in Valdebebas, Madrid, Spain

SINGAPORE, Nov. 01, 2026 (GLOBE NEWSWIRE) — Hotel101 Global Holdings Corp. (NASDAQ: HBNB) (“Hotel101 Global,” “Hotel101,” “HBNB” or the “Company”) today announced that the monthly performance of its 680-room Hotel101-Madrid has significantly exceeded the Company’s expectations. In October 2026, Hotel101-Madrid achieved a record high of €2.93¹ million (equivalent to approx. US$3.28 million) in recurring revenues from stays during the month, with average occupancy of 97.41%.

This record performance reflects the continued momentum and exceptionally strong demand for Hotel101-Madrid, the first Hotel101-branded property to operate outside the Philippines, which opened in March 2026. The Company believes the results provide clear evidence of robust underlying demand in a major European market and demonstrates Hotel101-Madrid’s ability to generate recurring revenues at scale. Management believes this property’s October performance is indicative of Hotel101’s potential to contribute meaningful annual recurring hotel revenues and further validates the Company’s asset-light, prop-tech hospitality model and its emphasis on long-term, recurring revenue generation across the Hotel101 global portfolio.

Key Operating Highlights – Hotel101-Madrid (October 2026)

• Monthly recurring revenue from October 2026 stays: €2,929,778¹ (a property record for any single month)
• Average occupancy: 97.41%
• Property size: 680 standardized HappyRooms

The Company believes these results reflect the effectiveness of Hotel101’s globally standardized “HappyRoom” concept and tech-enabled operating platform in attracting demand. The high occupancy also benefits unit owners, who collectively receive 30% of monthly gross room revenues net of applicable taxes and statutory charges, distributed equally across all units and paid by the 16^th day of the following month.

Hotel101-Madrid serves as the global prototype of the Hotel101 concept and primary operating springboard for the Company’s international expansion. Located in the dynamic Valdebebas district, just minutes from Adolfo Suárez Madrid-Barajas International Airport and IFEMA, one of Europe’s largest convention and exhibition centers, the 680-room property sits adjacent to the Real Madrid Sports City and the Formula 1 Spanish Grand Prix circuit, placing it at the heart of Madrid’s premier sports and events zone.

Hotel101-Madrid has demonstrated strong international guest appeal, earning a 9.1 “Exceptional” rating based on more than 9,700 reviews across major online travel agencies as of October 31, 2026. Since opening in March 2026 through October 31, 2026, arrivals have been led by guests from Spain (39%), the United States (7%), Portugal (4%), China (3%), and Mexico (3%), reflecting strong appeal across multiple continents. Europe has accounted for nearly two-thirds of all arrivals (63.3%), followed by Latin America (16.1%), North America (8.5%), and Asia (6.2%). With guests from over 100 nationalities, including a growing number of Filipinos (0.55% of the more than 95,500 arrivals since opening in March 2026), Hotel101-Madrid has rapidly established itself as an international destination.

Management expects Hotel101-Madrid’s performance to support the replication of the Hotel101 business model through joint ventures and, in the future, license agreements, advancing Hotel101 Global’s long-term vision of developing one million standardized rooms across 100 countries and its aspiration to become one of the top hotel brands globally.

About Hotel101 Global

Listed on Nasdaq (Ticker: HBNB) with a market capitalization of approx. US$1.11 billion as of October 30, 2026, Hotel101 is an asset-light, prop-tech hospitality platform pioneering a globally standardized “condotel” business model. Hotel101 aims to disrupt the global hotel and hospitality sector through its unique tech-enabled business model that positions it to generate revenues twice: first from the advance sale of individual hotel units during the construction phase; and second, from long-term recurring revenue derived from day-to-day hotel operations. The expansion of Hotel101 toward its long-term goal to operate in 100 countries globally is expected to be driven mainly by joint ventures and, in the future, license agreements with local developers in various countries worldwide.

Hotel101 is advancing its global expansion plans toward its medium-term goal to be in 25 countries and its long-term goal of operating one million Hotel101 rooms in 100 countries globally.

¹ _{The monthly recurring revenue figure in this release is a preliminary, unaudited management estimate based on information available as of the date of this release, relates only to stays at Hotel101-Madrid in October 2026 and are subject to change.}

Latest Photo of 680-room Hotel101-Madrid in Valdebebas, Madrid, Spain

Forward-Looking Statements

This document includes certain “forward-looking statements” within the meaning of securities laws of certain jurisdictions, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this document, including statements regarding the future financial position, business strategy, plans and objectives of management for future operations of Hotel101 Global Holdings Corp. (“HBNB”) and its subsidiaries (the “HBNB Group”), are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “set,” “expect,” “aim,” “goal,” “predict,” “potential” or the negative of these terms or other similar expressions. Forward-looking statements include, without limitation, HBNB’s expectations concerning anticipated recurring hotel revenues, the replication of its business model, expected number of rooms and expansion goals, the outlook for the HBNB Group’s business, productivity, plans and goals for future operational improvements and capital investments, operational performance, future market conditions or economic performance and developments in the capital and credit markets and expected future financial performance, as well as any information concerning possible or assumed future results of operations of the HBNB Group. These forward-looking statements are based on the beliefs and assumptions of the management of HBNB. Although HBNB believes that such plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, HBNB cannot assure you that such plans, intentions or expectations will be achieved or realized. Forward-looking statements involve a number of risks, uncertainties and assumptions and actual results or events may differ materially from those projected or implied in those statements. Results for any single month are not necessarily indicative of results for any future period. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, the HBNB Group’s ability to execute on its business model, potential business expansion opportunities in foreign countries and growth strategies, manage future growth, retain and expand customers’ use of its hotel services and attract new customers, and source and maintain talent; risks relating to joint venture partners, including owners of pre-sold condotel units in Hotel101 hospitality projects, who may have interests different from and may take actions that adversely affect the HBNB Group; risks relating to project cost and completion; risks relating to the HBNB Group’s sources of cash and cash resources; risks relating to offering deferred payment schemes, including the risk of customer default; the HBNB Group’s ability to effectively compete in the highly competitive hospitality industry; seasonality and fluctuations in hotel demand; any declines or disruptions in the travel and hospitality industries or economic downturn; applicable laws and regulations to real estate development and marketing activities and hotel operation and management activities in the jurisdictions where the HBNB Group has operations or intends to expand into; and other risks and uncertainties discussed in HBNB’s annual report for the year ended December 31, 2025 on Form 20-F and under the heading “Risk Factors” in HBNB’s registration statement on Form F-4 (File No.: 333-287130) and other documents to be filed by HBNB from time to time with the U.S. Securities and Exchange Commission.

The foregoing list of factors is not exhaustive. Should one or more of these risks or uncertainties materialize, or should any of HBNB’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. There may be additional risks that are not presently known to HBNB or that HBNB currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. HBNB cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date hereof. Forward-looking statements set forth herein speak only as of the date of this document. HBNB does not undertake any obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs. In the event that any forward-looking statement is updated, no inference should be made that HBNB will make additional updates with respect to that statement, related matters or any other forward-looking statements.

Contact: ir@hotel101global.com 

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/54be93ac-8205-481a-8642-bcd368b75ac7 

https://www.globenewswire.com/NewsRoom/AttachmentNg/0cd94511-514c-4f73-b310-1abfc5a9a419 

ORLANDO, Fla., Nov. 01, 2026 (GLOBE NEWSWIRE) — MicroVision, Inc. (NASDAQ: MVIS), a leader in advanced perception solutions for industrial, security and defense, and automotive applications, today announced an expanded collaboration with FieldAI, a developer of autonomous robotic systems for government and industrial applications.

The collaboration builds on successful testing of MicroVision’s perception technologies by FieldAI’s Federal team, including evaluation of the IRIS™ long-range lidar sensor on autonomous ground vehicles and demonstrations of MicroVision’s extended perception solution combining the Robinson Unmanned Spirit drone platform with the MOVIA™ Air Plus sensor for real-time, colorized 3D lidar mapping integrated with ATAK. In addition, FieldAI has purchased MicroVision MOVIA sensors for development and evaluation activities spanning both government and industrial autonomous robotics initiatives.

“FieldAI is pioneering autonomous systems designed for some of the most demanding operational environments, and we’re excited to continue expanding our collaboration across both their Federal and Industrial organizations,” said Glen DeVos, CEO of MicroVision. “From long-range perception for autonomous ground vehicles to real-time 3D mapping and short-range obstacle detection, our portfolio provides the flexibility and performance required to support next-generation robotic systems. We look forward to supporting FieldAI as they continue advancing autonomy across commercial and government applications.”

“The performance and versatility of MicroVision’s sensing technologies have made them an important collaborator as we continue advancing autonomous capabilities across our platform portfolio,” said Shehryar Khattak, Director of Technology at FieldAI. “Following successful tests across uncrewed ground and aerial systems, we are expanding our evaluation efforts to identify opportunities for broader adoption of MicroVision’s perception solutions across both our Federal and Industrial programs.”

The collaboration reflects growing demand for advanced perception solutions capable of supporting autonomous mobility, navigation, mapping, obstacle detection, and mission execution across government and industrial robotic platforms. By combining MicroVision’s portfolio of long-range, short-range, and aerial perception solutions with FieldAI’s autonomy software and robotic systems expertise, the companies are exploring opportunities to accelerate deployment of next-generation autonomous capabilities in challenging operational environments.

About Field AI

FieldAI is the leader in deploying general-purpose robots in unstructured environments, providing frontier autonomy software as a universal “brain” that works across many robots and many tasks. The company’s Field Foundation Models™ uniquely combine data-driven AI with physics-based reasoning and uncertainty awareness, enabling safe and reliable operations in environments previously considered too unpredictable for robots. FieldAI’s leadership team brings together world-class expertise in AI foundation models and real-world robotics, with roots in Google DeepMind, NASA JPL’s Mars exploration program, and DARPA’s Subterranean Challenge and RACER programs. The company has raised over $400 million from investors including Bezos Expeditions, Emerson Collective, Khosla Ventures, Canaan Partners, NVentures (NVIDIA’s venture capital arm), Prysm Capital, Temasek, and others. For more information, visit www.fieldai.com or contact PR@fieldai.com.

About MicroVision

MicroVision is defining the next generation of lidar-based perception solutions for industrial, security & defense, and automotive markets. As the industry moves beyond proof of concept toward value, deployment, and commercialization, MicroVision delivers integrated hardware and software solutions designed for real-world performance, automotive-grade reliability, and economic scalability. With engineering centers in the U.S. and Germany, MicroVision leads the industry in depth and breadth of its portfolio, with both short- and long-range lidar solutions, featuring solid-state sensors with varying wavelengths, advanced sensor architectures, design-to-cost engineering, and open software solutions.

For more information, visit the company’s website at www.microvision.com, on Facebook at https://www.facebook.com/MicrovisionInc/, and LinkedIn at https://www.linkedin.com/company/microvision/.

MicroVision, MicroVision HALO, IRIS, MOVIA, MOSAIK, and SENTINEL are trademarks of MicroVision, Inc., and SCANTINEL is a trademark of Scantinel GmbH, in the United States and other countries. All other trademarks are the property of their respective owners.

Investor Relations Contact

Jeff Christensen
Darrow Associates Investor Relations
MVIS@darrowir.com

Media Contact

Heidi Davidson – For MicroVision
heidi@galvanizeworldwide.com
(914) 441-6862

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1da378d3-deeb-4d93-9482-ea28611b4e49

Perth, Australia – November 2, 2026 – Atos, a global leader of AI-powered digital transformation, today announces the appointment of Judith Stewart as Head of Healthcare & Life Sciences for Asia Pacific, reinforcing the company’s commitment to accelerating growth and innovation across the sector and helping organizations harness the potential of artificial intelligence, sovereign technologies and cybersecurity.

Judith brings more than 18 years of international healthcare leadership experience, with a strong track record delivering healthcare reforms and transformations for public and private sector organizations across Australia and the UK. Prior to joining Atos, she held Executive roles for several years within WA Health, most recently as Executive Director for Child and Adolescent Community Health Services in Perth, Western Australia.  

In her new role, Judith will lead Atos’ Healthcare & Life Sciences business across Asia Pacific, with a focus on accelerating growth, strengthening customer relationships, fostering innovation and supporting clients as they navigate an increasingly complex technology landscape.

Daniele Principato, EVP and Head of International Markets at Atos, said:
“Judith brings extensive healthcare leadership experience and a deep understanding of the challenges facing the sector. Her appointment strengthens our Healthcare & Life Sciences capabilities in Asia Pacific and our ability to help clients accelerate transformation while addressing critical priorities around AI, cybersecurity and digital sovereignty.”

Judith Stewart, Head of Healthcare & Life Sciences, Asia Pacific at Atos, said:
“I am delighted to join Atos and look forward to working with our talented teams, customers and partners across Asia Pacific. Healthcare and Life Sciences organizations are navigating significant change, and technology and AI have an important role to play in helping them transform and innovate. I look forward to helping our clients unlock that potential and deliver meaningful outcomes for the communities they serve.”

The appointment reflects Atos’ continued investment in Asia Pacific and its commitment to supporting Healthcare & Life Sciences organizations as they harness advanced technologies to transform healthcare delivery, strengthen resilience and drive sustainable innovation.

***

About Atos

Atos is the Atos Group brand dedicated to AI-powered, secure, end-to-end digital services. Atos designs, develops, and operates critical digital environments that drive performance, resilience and sovereignty, helping public and private organizations worldwide retain control over their data and infrastructures, while meeting regulatory requirements.

With more than 51,000 employees serving over 4,500 clients across 54 countries, Atos helps modernize core IT systems, accelerate cloud and data transformation, strengthen cybersecurity, and deliver secure digital workplace environments to support its clients, its employees and society. Atos also provides consulting and advisory services through its Atos Amplify brand.

A trusted partner in operating complex and mission-critical environments, Atos supports organizations across highly regulated and sovereign contexts.

About Atos Group

Atos Group is a global leader in digital transformation with c. 53,000 employees and annual revenue of c. €7.2 billion, operating in 54 countries under two brands – Atos for services and Eviden for products and systems. European number one in cybersecurity and a leader in cloud, Atos Group is committed to a secure and decarbonized future and provides tailored AI-powered, end-to-end solutions for all industries. Atos Group is listed on Euronext Paris.

Press contact

lucie.leonardi@atos.ai

Attachment

• Judith Stewart

— Follows US FDA new drug application submission in September 2026, marking important global regulatory progress —

— Filings supported by positive SAFFRON global Phase III data demonstrating statistically significant and clinically meaningful PFS and OS improvements —

— Data selected for ESMO 2026 Presidential Symposium and simultaneously published in The New England Journal of Medicine —

HONG KONG and FLORHAM PARK, N.J., Nov. 01, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces that regulatory filings for ORPATHYS^® (savolitinib) in combination with TAGRISSO^® (osimertinib) have been accepted for review in Europe and Japan.

In Europe, the European Medicines Agency (EMA) has validated and accepted for regulatory review the Marketing Authorization Application (MAA) submitted by AstraZeneca, seeking approval for the combination for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) whose tumors have MET overexpression or amplification, and who had disease progression on or after an epidermal growth factor receptor (“EGFR”) tyrosine kinase inhibitor (“TKI”) therapy.

In Japan, AstraZeneca has submitted a New Drug Application (“NDA”) to the Ministry of Health, Labour and Welfare (MHLW), which has also been accepted for review, seeking approval in patients with unresectable, advanced or recurrent NSCLC whose tumors have MET overexpression or amplification, and who had disease progression following EGFR-TKI therapy.

These filings in Europe and Japan follow the submission of an NDA for the same combination to the US Food and Drug Administration (FDA) in September 2026, marking further progress in expanding global access to this innovative targeted combination therapy.

The regulatory filings are supported by positive results from the SAFFRON global Phase III trial. These results have been presented in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2026 and simultaneously published in The New England Journal of Medicine.  

ORPATHYS^® plus TAGRISSO^® demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (“PFS”) and overall survival (“OS”) versus doublet platinum-based chemotherapy in patients who progressed on treatment with TAGRISSO^®. ORPATHYS^® plus TAGRISSO^® reduced the risk of disease progression or death by 45% compared to chemotherapy (based on a PFS hazard ratio [“HR”] of 0.55; 95% confidence interval [“CI”] 0.42-0.72; p<0.001). Median PFS as assessed by blinded independent central review (BICR) was 7.6 months for ORPATHYS^® plus TAGRISSO^® versus 5.4 months for the comparator arm. Results for the key secondary endpoint of OS showed ORPATHYS^® plus TAGRISSO^® reduced the risk of death by 32% versus chemotherapy (OS HR 0.68; 95% CI 0.50-0.91; p=0.010). ORPATHYS^® plus TAGRISSO^® extended median OS by 4.9 months versus the comparator arm (17.8 versus 12.9 months). The safety profile was consistent with the known profiles of each medicine, and there were no new safety concerns.

Third-generation EGFR-TKIs have significantly improved outcomes for patients with EGFRm NSCLC. However, MET overexpression or amplification is one of the most common mechanisms of resistance on third-generation EGFR-TKI treatment. MET-driven progression is associated with poor prognosis, and there remains a significant unmet need for effective and well-tolerated treatment options in this setting.

ORPATHYS^® is being jointly developed by AstraZeneca and HUTCHMED and is commercialized by AstraZeneca.

About NSCLC and MET aberrations

Lung cancer is the leading cause of cancer death globally, accounting for almost one in four (23%) cancer deaths.^1,2 Lung cancer is broadly split into NSCLC and small cell lung cancer, with 80-85% of patients diagnosed with NSCLC.³ Approximately 75% of NSCLC patients are diagnosed with advanced disease.⁴ Additionally, about 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients in Asia, have EGFRm NSCLC.^​5

MET is a tyrosine kinase receptor that has an essential role in normal cell development.⁶ MET overexpression or amplification can lead to tumor growth and the metastatic progression of cancer cells.^6,7 Approximately one in three patients’ tumors will develop high levels of MET overexpression or amplification (IHC3+>90% and FISH10+) after progression on a third-generation EGFR-TKI.⁸

About SAFFRON

SAFFRON is a randomized, open-label, multi-center, global Phase III trial studying the efficacy of ORPATHYS^® (300 mg twice daily) added to TAGRISSO^® (80 mg once daily) versus doublet platinum-based chemotherapy in 338 patients with EGFRm, locally advanced or metastatic NSCLC with MET overexpression or amplification whose disease progressed following first- or second-line treatment with TAGRISSO^®. The trial enrolled patients in 230 centers across 29 countries in North America, Europe, South America and Asia. The primary endpoint is PFS and key secondary endpoint includes OS.

Patients were prospectively selected for SAFFRON using the high MET level cut-offs identified in the SAVANNAH Phase II trial. ​In SAVANNAH, MET overexpression or amplification levels were determined by two tests: immunohistochemistry (IHC), which detects if cancer cells have a particular protein or marker on their surface, and fluorescence in situ hybridization (FISH), which detects a specific DNA sequence from cancer cells.

About ORPATHYS^®

ORPATHYS^® (savolitinib) is an oral, potent and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression.

ORPATHYS^® is approved in China for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration, representing the first selective MET inhibitor approved in China. ORPATHYS^® also received a conditional approval in China for the treatment of adult patients with locally advanced or metastatic gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma patients with MET amplification who have failed at least two prior systemic treatments. ORPATHYS^® in combination with TAGRISSO^® is approved in China for patients with locally advanced or metastatic EGFR mutation-positive non-squamous NSCLC with MET amplification after disease progression on EGFR TKI therapy based on the SACHI Phase III trial. The combination was also granted a temporary authorization in Switzerland for the treatment of patients with locally advanced or metastatic EGFRm NSCLC and high levels of MET overexpression or amplification who progressed on prior treatment with TAGRISSO^®. This was based on results from the global SAVANNAH Phase II trial. The global, randomized, SAFFRON Phase III trial in the same treatment setting comparing the combination with doublet platinum-based chemotherapy reported positive high-level results, demonstrating a statistically significant and clinically meaningful improvement in PFS and OS in August 2026.

About TAGRISSO^®

TAGRISSO^® (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including the treatment of central nervous system metastases.

TAGRISSO^® is approved as monotherapy in more than 120 countries including the US, EU, China and Japan. Approved indications include for first-line treatment of patients with locally advanced or metastatic EGFRm NSCLC, locally advanced or metastatic EGFR T790M mutation-positive NSCLC, adjuvant treatment of early-stage EGFRm NSCLC and locally advanced, unresectable NSCLC following platinum-based chemoradiation therapy. TAGRISSO^® is also approved in combination with chemotherapy in more than 80 countries, including the US, EU, China and Japan, for first-line treatment of patients with locally advanced or metastatic EGFRm NSCLC.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of ORPATHYS^®, the further clinical development for ORPATHYS^®, its expectations as to whether any studies on ORPATHYS^® would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of ORPATHYS^®, including as a combination therapy, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of ORPATHYS^® for a targeted indication; the sufficiency of funding; HUTCHMED’s and AstraZeneca’s ability to successfully develop and commercialize ORPATHYS^®. In addition, as certain studies rely on the use of other drug products such as TAGRISSO^® as combination therapeutics with ORPATHYS^®, such risks and uncertainties include assumptions regarding the safety, efficacy, supply and continued regulatory approval of these therapeutics. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries	+852 2121 8200 / ir@hutch-med.com
Media Enquiries
FTI Consulting –	+44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500
Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500
Deutsche Numis	Joint Broker
Duncan Monteith / Ramin Naji	+44 20 7545 8000

¹  World Health Organization. International Agency for Research on Cancer. Lung Fact Sheet. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf. Accessed October 2026.
²  World Health Organization. International Agency for Research on Cancer. All Cancers Fact Sheet. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/39-all-cancers-fact-sheet.pdf. Accessed October 2026.
³  American Cancer Society. What Is Lung Cancer? Available at: https://www.cancer.org/cancer/types/lung-cancer/about/what-is.html. Accessed August 2026.
⁴  Chen HJ, et al. Long-term survival of advanced lung adenocarcinoma by maintenance chemotherapy followed by EGFR-TKI. Medicine. 2021;100(6):e24688.
⁵  Gao X, et al. The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer. Expert Rev Anticancer Ther. 2016;16(4):383-390.
⁶  Uchikawa E, et al. Structural basis of the activation of c-MET receptor. Nat Commun. 2021;12(4074)
⁷  Wang Q, et al. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol. 2019;63.
⁸  De Marinis F, et al. Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study. Ann Oncol. 2025;36(8):920-933.

NEW YORK, Nov. 01, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced rotational changes and retirement of certain members of its Board, and reiterated its intention to add new members with the requisite global commercial experience in the biopharmaceutical sector in line with its next phase of commercial delivery and growth.

After 12 years of serving on the Board since 2014, Mr William Burns will retire from the Board at the Company’s 2026 Annual General Meeting. Ms Jane Bell AM will take over as Chair of the Nomination and Remuneration Committee, having been co-Chair with Mr Burns since April 2026. The Board recognizes the contribution by Mr Burns to the Company’s strategic direction and corporate governance.

Dr Philip Krause will also retire from the Board, after having been a director since 2022. Dr Krause has provided regulatory and clinical development expertise as a Board member and consultant to Mesoblast after a long career at the U.S. Food and Drug Administration (FDA). The Board recognizes his significant contribution to activities by the Mesoblast team which advanced Ryoncil^® (remestemcel-L-rknd) to FDA approval.

Chair Mr Philip Facchina said, “On behalf of the Board, I wish to thank Mr Burns for his broad contributions spanning more than a decade and Dr Krause for his significant contribution to Mesoblast as a director. The Company is now a revenue-generating commercial enterprise following the successful launch of RYONCIL in the United States. In line with this, we plan to recruit and appoint new directors with U.S. and global commercial expertise in the biotechnology and pharmaceutical sectors.”

About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast’s Ryoncil^® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.

Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil^® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.

About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.

About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and X: @Mesoblast

Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For more information, please contact:

Corporate Communications / Investors
Paul Hughes
T: +61 3 9639 6036
Media – Global	Media – Australia
Rubenstein	BlueDot Media
Caroline Nelson	Steve Dabkowski
T: +1 703 489 3037	T: +61 419 880 486
E: cnelson@rubenstein.com	E: steve@bluedot.net.au

MINNEAPOLIS and BRISBANE, Australia, Nov. 01, 2026 (GLOBE NEWSWIRE) — Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced 30-day clinical and hemodynamic outcomes for the Medium-size DurAVR^® Transcatheter Heart Valve (THV) in twenty-two severe aortic stenosis patients with medium aortic annuli (aortic annulus area 492 ± 38 mm²). The DurAVR THV demonstrated single digit mean gradients, large effective orifice areas (EOAs), no moderate or severe paravalvular leaks and no valve related mortality, with 100% freedom from moderate or severe prosthesis-patient mismatch^* (PPM) in a cohort of medium annuli patients from the EMBARK Study.

The 30-day Medium-size DurAVR THV results were presented by Azeem Latib, MD during the Emerging Concepts and Innovations in TAVR session at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Diego, California.

30-day Results Highlights

• DurAVR THV delivered a favorable hemodynamic profile with a large EOA of 2.64 ± 0.19 cm² (baseline 0.8 ± 0.2 cm²) and a single digit mean pressure gradient (MPG) of 6.17 ± 1.40 mmHg (baseline 45.5 ± 11.7 mmHg). 
• At 30-days, clinical safety outcomes were positive with no valve related mortality and no moderate or severe paravalvular leak (PVL).
• No moderate or severe prosthesis–patient mismatch was observed at 30 days.

“These are exceptional 30-day hemodynamics for medium annuli, with large effective orifice areas, single-digit gradients, and no moderate or severe PPM or paravalvular leak. That matters because prosthesis-patient mismatch is not just a small-annulus problem. A recent study in younger, lower-risk TAVR patients found PPM was associated with higher mortality and substantially more heart failure hospitalization at five years.¹ As TAVR moves to patients who will live with their valve for decades, this is the hemodynamic profile we designed DurAVR to deliver, and we look forward to PARADIGM confirming it in a randomized setting,” said Chris Meduri, M.D., Anteris Chief Medical Officer.

The DurAVR THV is being evaluated in the ongoing global PARADIGM pivotal trial (ClinicalTrials.gov ID NCT07194265), which is actively enrolling patients and will include use of the Medium-size DurAVR THV. This prospective, randomized controlled trial (RCT) is designed to evaluate the safety and effectiveness of DurAVR THV compared to commercially available transcatheter aortic valve replacements (TAVRs) in the treatment of severe aortic stenosis.

^{¹Suruga K, et al. Prosthesis-Patient Mismatch in Young and Low-Risk Patients After Newer Generation Balloon-Expandable Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2025;18(12).}

^{*Prosthesis‐patient mismatch (PPM) happens when a prosthetic valve, after being implanted, doesn’t have a large enough opening (EOA) to accommodate the patient’s blood flow needs, based on their body size. The result is higher than expected gradients. PPM affects a significant proportion of transcatheter aortic valve (TAVR) patients, particularly patients with a small aortic annulus and has been associated with impaired long-term survival following surgical aortic valve replacement (SAVR).}

^{**As defined in VARC-3}

About the PARADIGM Trial

The PARADIGM Trial is a prospective randomized controlled trial which will evaluate the safety and effectiveness of the DurAVR Transcatheter Heart Valve compared to commercially available transcatheter aortic valve replacements (TAVRs).

This head-to-head study will enrol approximately 1,000 patients in the ‘All Comers Randomized Cohort’ with 1:1 randomization of patients who will receive either the DurAVR THV or TAVR using commercially available and approved THVs. The PARADIGM Trial will assess non-inferiority on a primary composite endpoint of all-cause mortality, all stroke and cardiovascular hospitalization at one year post procedure.

For further information, please refer to ClinicalTrials.gov NCT07194265.

About Anteris

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris’ lead product, the DurAVR THV, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR THV is made using a single piece of molded ADAPT^® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR THV System is comprised of the DurAVR valve, the ADAPT tissue, and the balloon-expandable ComASUR^® Delivery System.

DurAVR THV is intended for INVESTIGATIONAL USE ONLY. Not available for commercial use or sale worldwide. CAUTION—Investigational device. Limited by Federal (or United States) law to investigational use.

Forward-Looking Statements

This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K for the fiscal period ended December 31, 2025 that was filed with the Securities and Exchange Commission and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.   

For more information:
Global Investor Relations	Investor Relations (US)
investors@anteristech.com	mchatterjee@bplifescience.com
Debbie Ormsby	Malini Chatterjee, Ph.D.
Anteris Technologies Global Corp.	Blueprint Life Science Group
+61 1300 550 310 | +61 7 3152 3200	+1 917 330 4269

Website	www.anteristech.com
X	@AnterisTech
LinkedIn	https://www.linkedin.com/company/anteristech

Late-Breaking P4 study, simultaneously published in NEJM, shows CT guidance delivers matched one-year clinical outcomes with shorter procedures, demonstrating pre-procedural CCTA can guide key PCI planning decisions

NAVIGATE-PCI shows Heartflow PCI Navigator drove modifications to stent length and lesion prep compared to angiography alone

SAN FRANCISCO, Nov. 01, 2026 (GLOBE NEWSWIRE) — Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced new landmark randomized clinical data presented at Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, demonstrating computed tomography (CT)-guided percutaneous coronary intervention (PCI) matches gold-standard imaging outcomes with greater efficiency. These data are supported by registry insights on the procedural impact of Heartflow PCI Navigator.

In a late-breaking presentation simultaneously published in the New England Journal of Medicine (NEJM), the 1,105-patient P4 randomized clinical trial met its primary endpoint, demonstrating that CT-guided PCI planning was non-inferior to gold-standard intravascular ultrasound (IVUS) for one-year clinical outcomes. In the largest randomized trial of its kind, CT guidance achieved these matched results compared to IVUS while significantly improving procedural efficiency, delivering faster procedure times and utilizing lower contrast volume. Data from the NAVIGATE-PCI registry showed that interventional cardiologists altered their procedural strategy in approximately 70% of cases after incorporating 3D anatomic, plaque, and physiologic insights from Heartflow PCI Navigator compared to standard invasive coronary angiography alone.

“CT has already become routine for planning structural procedures like TAVR. The data presented at TCT show coronary intervention is ready to follow the same path with advanced pre-procedural imaging and Heartflow’s AI-powered analysis to deliver precision and efficiency,” said Campbell Rogers, M.D., F.A.C.C., Chief Medical Officer at Heartflow. “What we learned planning P4 cases across six separate tools shaped Heartflow PCI Navigator, which brings anatomy, plaque and physiology together in the first and only PCI planning tool backed by prospectively validated accuracy and randomized clinical trial data. Together, P4 and NAVIGATE-PCI support a paradigm shift in coronary intervention, bringing non-invasive CT-guided PCI planning into routine cath lab practice.”

P4 Trial: Validating CT-guided PCI Against IVUS with Greater Efficiency
Main Arena 4, November 1

The Heartflow-supported, investigator-initiated P4 trial directly evaluated the clinical efficacy of non-invasive CT-guided PCI planning against invasive IVUS guidance.

Enrolling 1,105 patients across 23 centers in the U.S., Europe, and Japan, P4 randomized stable CAD patients to either CT-guided PCI planning, including Heartflow FFR_CT Analysis and Heartflow Planner (an earlier version of Heartflow PCI Navigator), or intra-procedural IVUS guidance.

Key P4 trial one-year findings showed CT-guided PCI matched IVUS on outcomes while enabling a faster procedure and lower contrast use, including:

• CT-guided PCI matched IVUS for the primary endpoint of 12-month target-vessel failure (4.1% vs. 4.6%).
• CT-guided PCI had a 17-minute shorter median procedure time than IVUS (46 minutes vs. 63 minutes, a 27% reduction).
• Contrast volume was reduced by approximately 12% in the CT-guided arm (median 150 mL vs. 170 mL).
• CT-guided PCI more than doubled the use of advanced calcium modification (9.2% vs. 3.8%).

“Intravascular ultrasound is an established benchmark, but performing assessments inside the cath lab adds procedural time and requires expertise,” said Carlos Collet, M.D., Ph.D., principal investigator of the P4 trial and Director of Cardiovascular Imaging, Physiology and Translational Therapeutics at the Cardiovascular Research Foundation in New York. “P4 shows that non-invasive CT-guided PCI planning achieves comparable clinical outcomes with shorter procedure times and less contrast, enabling interventionalists to anticipate challenges, tailor their strategy, and enter the cath lab better prepared.”

NAVIGATE-PCI Registry: Optimizing Strategy Before Entering the Cath Lab
TCT AI Lab 3, November 1

NAVIGATE-PCI is a prospective, multi-center registry evaluating the real-world utility of Heartflow PCI Navigator, the first and only integrated, AI-driven PCI planning tool that gives interventional cardiologists a patient-specific 3D model detailing anatomy, plaque composition, and lesion-specific physiology, all aligned to streamline procedures with increased efficiency and clinical confidence. In the 203-patient cohort presented at TCT, investigators evaluated how access to integrated pre-procedural insights altered treatment strategies established immediately after invasive angiography.

Key NAVIGATE-PCI findings include:

• Treatment plans were modified in approximately 70% of patients after physicians reviewed Heartflow PCI Navigator prior to intervention, compared to angiography alone. The most frequent changes included stent length (41%) and lesion preparation technique (12%).
• Physicians rated their PCI Navigator plans with higher confidence than their angiography-based plans.

“Angiography only shows a two-dimensional silhouette, leaving critical blind spots around plaque burden, calcium and true vessel size,” said Ziad A. Ali, M.D., D.Phil., principal investigator of the NAVIGATE-PCI registry and Director of the DeMatteis Cardiovascular Institute at St. Francis Heart Center in New York. “Heartflow PCI Navigator fundamentally changes our approach, providing the comprehensive 3D and physiologic clarity needed to tailor treatment plans with greater confidence before entering the cath lab.”

The BRAVEHEART Registry: Revealing High CAD Burden in Firefighters to Accelerate Prevention
TCT 1488, November 3

Highlighting the impact of Heartflow’s technology across the entire continuum of care, investigators will also present data from the prospective BRAVEHEART registry. The study evaluated the use of AI-powered Heartflow Plaque Analysis and Heartflow FFR_CT Analysis to identify hidden coronary risk and encourage earlier preventive therapy in 96 asymptomatic firefighters with at least 10 years of occupational smoke exposure.

Key BRAVEHEART findings include:

• Subclinical coronary plaque was identified in 72% of asymptomatic firefighters (mean age 48.1 years), with 16% presenting with severe total plaque volume (>250 mm³).
• Willingness to initiate lipid-lowering medical therapy was reported by 68% of participants following review of their CCTA and Heartflow Analysis insights, while 93% committed to lifestyle modifications.

Experience Heartflow PCI Navigator at TCT 2026

TCT 2026 attendees are invited to visit Heartflow at exhibit booth #3819 for live demonstrations of Heartflow PCI Navigator. See the full schedule of other Heartflow programs, including a lunch symposium, hands-on training workshops, and more at event.heartflow.com/tct2026.

About Heartflow PCI Navigator

Heartflow expanded the Heartflow One platform with the addition of Heartflow PCI Navigator to support diagnosing, managing and guiding treatment for patients throughout the spectrum of CAD care. PCI Navigator is the only integrated, AI-driven percutaneous coronary intervention (PCI) planning tool that gives interventional cardiologists a patient-specific 3D model detailing anatomy, plaque composition, and lesion-specific physiology, all aligned to optimize potential stent placement. Heartflow introduced PCI Navigator to close the critical information gaps interventional cardiologists face before entering the cardiac catheterization lab.

About Heartflow Plaque Analysis with Plaque Staging

Heartflow Plaque Analysis is the only FDA-cleared, AI-powered plaque analysis tool with 95% agreement against the gold standard, intravascular ultrasound (IVUS), in a prospective, international trial.¹ Heartflow Plaque Staging builds on this foundation, categorizing plaque burden into clinical risk stages to guide actionable risk stratification.^2,3 The framework is validated in 23,000 patients with up to 16 years of follow-up, offering the reproducibility clinicians need for serial monitoring and individualized preventive care.

About Heartflow’s Technology and Research

Heartflow’s technology is redefining precision diagnostic testing and management for coronary artery disease (CAD) through clinically proven AI and the world’s largest coronary imaging dataset. Heartflow has been adopted by more than 1,800 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population. Backed by American College of Cardiology and American Heart Association (ACC/AHA) guidelines and supported by more than 625 peer-reviewed publications, Heartflow has redefined how clinicians manage care for over 750,000 patients worldwide.⁴ Key benefits include:

• Unmatched proprietary data pipeline: Built from the world’s largest database of more than 200 million annotated CTA images, Heartflow’s data foundation powers advanced AI models that deliver highly accurate, reproducible diagnostic insights across diverse patient populations.
• Extensive clinical and real-world validation: Heartflow’s AI-driven solutions have been validated through clinical evidence in over 200 studies assessing over 365,000 patients. Heartflow is the only AI platform prospectively validated against invasive gold standards and demonstrated through real-world evidence to improve patient outcomes.^3,5,6,7 Proven in real-world practice with reproducibility and accuracy, Heartflow’s coronary CTA image acceptance rates exceed 97%.
• Seamless clinical integration via upgraded workflow: Heartflow delivers final quality-reviewed analyses instantly upon order, enabling clinicians to move from diagnosis to decision without delay.
• Quality system, global security and patient-data integrity compliance: Heartflow meets or exceeds leading international standards, including HITRUST r2, SOC 2 Type 2, MDSAP, ISO 13485, and ISO 27001.

About Heartflow, Inc.

Heartflow is transforming coronary artery disease from the world’s leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The Heartflow One platform uses AI to turn coronary CTA images into personalized 3D models of the heart, providing clinically meaningful, actionable insights into plaque location, volume, and composition and its effect on blood flow — all without invasive procedures. Discover how we’re shaping the future of cardiovascular care at heartflow.com.

Media Contact
Elliot Levy
elevy@heartflow.com

Investor Contact
Nick Laudico
nlaudico@heartflow.com

_____________________________
¹ Ihdayhid A, et al. Radiol Cardiothorac Imaging. 2024. doi: 10.1148/ryct.230312 and internal bridging study with ICC correlation between first generation and second generation Plaque Analysis algorithm.
² Rinehart, et al. JACC Imaging. 2025.
³ Fairbairn et al. Coronary CT Angiography Plaque as a Predictor of Death, Cardiovascular Death and Myocardial Infarction. Presented at AHA 2025. (Real-world study with n=7,899 patients, higher TPV results in increased cardiovascular death and MI)h
⁴ Gulati M, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCAI Guideline for the Evaluation and Diagnosis of Chest Pain. Circulation 2021; 144:e368–e454.
⁵ Narula, et al. EHJ CVI 2024.
⁶ Danad, et al. JAMA Cardiol 2017.
⁷ Madsen KT, et al. ADVANCE-DK 7-year. Presented at TCT Scientific Sessions 2024. (n=900 patients determined a 2.5x increase in cardiovascular events or deaths at 7 years).